Press Releases

Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide

TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received independent Institutional Review Board (IRB) approval for the Phase II trial of its lead drug LSALT peptide (Metablok) targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.

Read more

Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.

  • Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19)
  • Novel Mechanism of Action – a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
  • Investigational New Drug application activated and U.S. FDA permission to proceed with Phase II trial to treat complications in COVID-19 patients.
  • Phase 1 study in 52 healthy male and female volunteers is complete with LSALT peptide meeting primary endpoint of safety and tolerability.

Read more

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, June 30, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has closed the non-brokered private placement the Company disclosed in a press release June 24, 2020 (The “Offering”).

Read more

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private placement offering of up to 900,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $1,000,000 USD (approximately $1,350,000 CAD) (the “Offering”).

Read more

FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients

  • International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in patients infected with COVID-19
  • Novel Mechanism of Action – a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
  • Study also recently approved by Health Canada

TORONTO, June 16, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc.

(“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to proceed with a Phase II trial in the U.S. for its lead drug Metablok (LSALT peptide) to prevent acute lung and kidney injury experienced by patients with COVID-19.

Read more

Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)

  • International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19)
  • Novel Mechanism of Action – a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
  • Study also recently approved in Canada, additional filings made and planned globally
  • Phase 1 study in 52 healthy male and female subjects is complete with LSALT peptide meeting primary endpoint of safety and tolerability

Read more

Grant of Options

TORONTO, June 11, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that its Board of Directors has granted a total of 1,430,000 stock options to directors, officers and certain consultants pursuant to the Company’s stock option plan and the requirements of the TSX Venture Exchange (TSXV).

Read more

Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for its lead drug Metablok (LSALT peptide) to conduct a Phase II trial to prevent acute organ inflammation and injury experienced by patients with COVID-19.

Read more